公开(公告)号：US09334235B2

公开(公告)日：2016-05-10

申请号：US13141035

申请日：2009-12-18

Applicant: M. Amin Khan ,  Paul L. Wood ,  Dayan Goodenowe ,  Rishikesh Mankidy ,  Pearson Ahiahonu

Inventor： M. Amin Khan ,  Paul L. Wood ,  Dayan Goodenowe ,  Rishikesh Mankidy ,  Pearson Ahiahonu

IPC: C07C229/22 ,  C07C323/59 ,  C07C279/14 ,  C07D339/04 ,  C07F9/10

CPC classification number: C07C323/59 ,  C07C229/22 ,  C07C279/14 ,  C07D339/04 ,  C07F9/106

Abstract: Described herein are routes of synthesis and therapeutic uses of 1-alkyl, 2-acyl glycerol derivatives of formula I: which when administered to mammalian biological systems result in increased cellular concentrations of specific sn-2 substituted ethanolamine plasmalogens independent of the ether lipid synthesis capacity of the system. Elevating levels of the specific sn-2 substituted species in this way can cause lowering of membrane cholesterol levels and the lowering of amyloid secretion. These compounds can be used for the treatment or prevention of diseases of aging associated with increased membrane cholesterol, increased amyloid, and decreased plasmalogen levels, such as neurodegeneration (including Alzheimer's disease, Parkinson's disease and age-related macular degeneration), cognitive impairment, dementia, cancer (e.g. prostate, lung, breast, ovarian, and kidney cancers), osteoporosis, bipolar disorder and vascular diseases (such as atherosclerosis, hypercholesterolemia).

Abstract translation: 本文描述了式I的1-烷基，2-酰基甘油衍生物的合成途径和治疗用途：当向哺乳动物生物系统施用时，其导致独特于醚脂质合成能力的特异性sn-2取代的乙醇胺plasmalogen的细胞浓度增加 的系统。 以这种方式提高特定sn-2取代物种的水平可能导致膜胆固醇水平的降低和淀粉样蛋白分泌的降低。 这些化合物可用于治疗或预防与增加的膜胆固醇，增加的淀粉样蛋白相关的老化疾病和降低的血浆素水平，例如神经变性（包括阿尔茨海默病，帕金森病和年龄相关性黄斑变性），认知障碍，痴呆 ，癌症（例如前列腺癌，肺癌，乳腺癌，卵巢癌和肾癌），骨质疏松症，双相性精神障碍和血管疾病（如动脉粥样硬化，高胆固醇血症）。

公开(公告)号：US07348143B2

公开(公告)日：2008-03-25

申请号：US10508179

申请日：2003-03-20

Applicant: Douglas Heath ,  Dayan Goodenowe

Inventor： Douglas Heath ,  Dayan Goodenowe

IPC: C12Q1/68

CPC classification number: G06T11/206 ,  G06F19/26 ,  G06F19/28 ,  G06F19/708 ,  H01J49/0036 ,  H01J49/38

Abstract: The invention can be summarized as follows. The present invention provides a method of displaying spectroscopic data comprising in steps of, i) obtaining spectroscopic data from a plurality of samples, each sample comprising one or more components wherein each component is characterized by an ordered pair (X,Y) of data comprising data element value X and data element value Y, wherein X is a data element value, equivalent or directly proportional to the mass of the component, and Y is a data element value equivalent or directly proportional to the amount of the component; ii) identifying all unique components comprising a common data element value X in said samples; computing the average of all X therefrom; and determining the average and optionally, the standard deviation for all Y values from all ordered data pairs comprising a common X; iii) generating a data structure comprising an array of codable cells, each cell assigned a color or other identifiable characteristic based on the relationship of the amount of each unique component present in each of said samples in relation to a predetermined value or other characteristic of the spectroscopic data. Also disclosed are data structures comprising spectroscopic data.

Abstract translation: 本发明可概括如下。 本发明提供一种显示光谱数据的方法，包括以下步骤：i）从多个样本获得光谱数据，每个样本包括一个或多个分量，其中每个分量的特征在于数据的有序对（X，Y），包括 数据元素值X和数据元素值Y，其中X是与分量的质量相当或直接成比例的数据元素值，Y是与分量的量相当或直接成比例的数据元素值; ii）识别包括所述样本中的公共数据元素值X的所有唯一分量; 计算所有X的平均值; 以及从包括公共X的所有有序数据对中确定所有Y值的平均值和可选地的标准偏差; iii）生成包括可编码单元阵列的数据结构，每个单元基于存在于每个所述样本中的每个唯一分量的量与预定值或其他特征的相关性分配颜色或其他可识别特征 光谱数据。 还公开了包括光谱数据的数据结构。

公开(公告)号：US08273575B2

公开(公告)日：2012-09-25

申请号：US12670426

申请日：2008-07-25

Applicant: Dayan Goodenowe

Inventor： Dayan Goodenowe

IPC: G01N33/92 ,  G01N24/00

CPC classification number: G01N33/6848 ,  G01N33/6893 ,  G01N33/92 ,  G01N2405/00 ,  G01N2405/04 ,  G01N2800/30 ,  G01N2800/38 ,  Y10T436/24

Abstract: Methods for the diagnosis, risk assessment, and monitoring of Autism Spectrum Disorder (ASD) are disclosed. More specifically the present invention relates to the measurement of small molecules (metabolites) in human plasma that are found to have different abundances between persons with a clinical manifestation of ASD and subjects not expressing symptoms of ASD. Further, this invention relates to the monitoring of putative therapeutic strategies designed to ameliorate the biochemical abnormalities associated with ASD.

Abstract translation: 披露了自闭症谱系障碍（ASD）的诊断，风险评估和监测方法。 更具体地说，本发明涉及人类血浆中的小分子（代谢物）的测量，其发现具有ASD的临床表现的人与未表达ASD的症状的受试者之间具有不同的丰度。 此外，本发明涉及监测旨在改善与ASD相关的生化异常的推定治疗策略。

公开(公告)号：US20080255764A1

公开(公告)日：2008-10-16

申请号：US11910942

申请日：2006-09-12

Applicant: Shawn Ritchie ,  Dayan Goodenowe

Inventor： Shawn Ritchie ,  Dayan Goodenowe

IPC: C12Q1/00 ,  G01N33/574 ,  G01N33/50

CPC classification number: G01N33/57419 ,  G01N33/57449 ,  G01N33/57484 ,  G01N33/6848 ,  G01N33/82

Abstract: The present invention relates to the diagnosis of colorectal and ovarian cancers (CRC and OC, respectively). The present invention describes the relationship between endogenous small molecules and CRC or OC. Specifically, the present invention relates to the diagnosis of CRC and OC through the measurement of vitamin E isoforms and related metabolites. The present invention also relates to diagnostic markers identified in said method. The present invention relates to the underlying case and pre-symptomatic phases of CRC, the diagnosis of various stages and severity of CRC, the early detection of CRC, monitoring and diagnosing the effect of therapy on CRC and OC health states.

Abstract translation: 本发明涉及结肠直肠癌和卵巢癌的诊断（分别为CRC和OC）。 本发明描述了内源性小分子与CRC或OC之间的关系。 具体地，本发明涉及通过测量维生素E同种型和相关代谢物来诊断CRC和OC。 本发明还涉及在所述方法中鉴定的诊断标记物。 本发明涉及CRC的基础病例和症状前期，CRC的各种阶段和严重性的诊断，CRC的早期检测，监测和诊断治疗对CRC和OC健康状态的影响。

公开(公告)号：US20050107957A1

公开(公告)日：2005-05-19

申请号：US10508179

申请日：2003-03-20

Applicant: Douglas Heath ,  Dayan Goodenowe

Inventor： Douglas Heath ,  Dayan Goodenowe

IPC: G01N31/00 ,  G01N33/48 ,  G01N33/50 ,  G06F19/26 ,  G06F19/00

CPC classification number: G06T11/206 ,  G06F19/26 ,  G06F19/28 ,  G06F19/708 ,  H01J49/0036 ,  H01J49/38

Abstract: The invention can be summarized as follows. The present invention provides a method of displaying spectroscopic data comprising in steps of, i) obtaining spectroscopic data from a plurality of samples, each sample comprising one or more components wherein each component is characterized by an ordered pair (X,Y) of data comprising data element value X and data element value Y, wherein X is a data element value, equivalent or directly proportional to the mass of the component, and Y is a data element value equivalent or directly proportional to the amount of the component; ii) identifying all unique components comprising a common data element value X in said samples; computing the average of all X therefrom; and determining the average and optionally, the standard deviation for all Y values from all ordered data pairs comprising a common X; iii) generating a data structure comprising an array of codable cells, each cell assigned a color or other identifiable characteristic based on the relationship of the amount of each unique component present in each of said samples in relation to a predetermined value or other characteristic of the spectroscopic data. Also disclosed are data structures comprising spectroscopic data.

Abstract translation: 本发明可概括如下。 本发明提供一种显示光谱数据的方法，包括以下步骤：i）从多个样本获得光谱数据，每个样本包括一个或多个分量，其中每个分量的特征在于数据的有序对（X，Y），包括 数据元素值X和数据元素值Y，其中X是与分量的质量相当或直接成比例的数据元素值，Y是与分量的量相当或直接成比例的数据元素值; ii）识别包括所述样本中的公共数据元素值X的所有唯一分量; 计算所有X的平均值; 以及从包括公共X的所有有序数据对中确定所有Y值的平均值和可选地的标准偏差; iii）生成包括可编码单元阵列的数据结构，每个单元基于存在于每个所述样本中的每个唯一分量的量与预定值或其他特征的相关性分配颜色或其他可识别特征 光谱数据。 还公开了包括光谱数据的数据结构。

公开(公告)号：US20120136057A1

公开(公告)日：2012-05-31

申请号：US13387110

申请日：2010-07-29

Applicant: Shawn Ritchie ,  Dayan Goodenowe ,  M. Amin Khan ,  Pearson W.K. Ahiahonu

Inventor： Shawn Ritchie ,  Dayan Goodenowe ,  M. Amin Khan ,  Pearson W.K. Ahiahonu

IPC: A61K31/20 ,  A61P35/00 ,  A61P1/00 ,  A61P29/00 ,  H01J49/26 ,  C07K14/00 ,  C12N9/96 ,  C07F7/08 ,  C07C31/18 ,  C07C69/52 ,  C07C59/42 ,  G01N33/566

CPC classification number: A61K31/202 ,  C07C33/048 ,  C07C59/42 ,  C07C67/303 ,  C07C67/347 ,  C07C69/606 ,  C07C69/65 ,  C07C69/732 ,  G01N33/57407 ,  G01N33/57419 ,  G01N33/6893 ,  G01N2800/24 ,  A61K2300/00

Abstract: A compound of formula (I): wherein R represents a hydroxy substituted C24-C40 straight chain aliphatic group containing at least one double bond in the carbon chain; and at least one carbon in the chain is substituted with a hydroxy group. Such compounds are useful for detecting inflammation, inflammatory disorders and cancer in a subject, and can also be used in therapeutic applications including treatment and/or prevention of these conditions. Pharmaceutical compositions, combinations and supplements, as well as methods of treatment using the described compounds are therefore also described.

Abstract translation: 式（I）的化合物：其中R表示在碳链中含有至少一个双键的羟基取代的C24-C40直链脂族基团; 并且链中的至少一个碳被羟基取代。 这样的化合物可用于检测受试者中的炎症，炎性疾病和癌症，并且还可用于治疗应用，包括治疗和/或预防这些病症。 因此，还描述了药物组合物，组合和补充剂以及使用所述化合物的治疗方法。

公开(公告)号：US20110053287A1

公开(公告)日：2011-03-03

申请号：US12670426

申请日：2008-07-25

Applicant: Dayan Goodenowe

Inventor： Dayan Goodenowe

IPC: G01N24/00

CPC classification number: G01N33/6848 ,  G01N33/6893 ,  G01N33/92 ,  G01N2405/00 ,  G01N2405/04 ,  G01N2800/30 ,  G01N2800/38 ,  Y10T436/24

Abstract: Methods for the diagnosis, risk assessment, and monitoring of Autism Spectrum Disorder (ASD) are disclosed. More specifically the present invention relates to the measurement of small molecules (metabolites) in human plasma that are found to have different abundances between persons with a clinical manifestation of ASD and subjects not expressing symptoms of ASD. Further, this invention relates to the monitoring of putative therapeutic strategies designed to ameliorate the biochemical abnormalities associated with ASD.

Abstract translation: 披露了自闭症谱系障碍（ASD）的诊断，风险评估和监测方法。 更具体地说，本发明涉及人类血浆中的小分子（代谢物）的测量，其发现具有ASD的临床表现的人与未表达ASD的症状的受试者之间具有不同的丰度。 此外，本发明涉及监测旨在改善与ASD相关的生化异常的推定治疗策略。

公开(公告)号：US20100105101A1

公开(公告)日：2010-04-29

申请号：US12595178

申请日：2008-04-09

Applicant: Dayan Goodenowe

Inventor： Dayan Goodenowe

IPC: C12Q1/02

CPC classification number: G01N33/49 ,  G01N33/57484 ,  G01N33/6896 ,  G01N33/92 ,  G01N2560/00 ,  G01N2800/50 ,  G01N2800/7042 ,  H01J49/0031 ,  H01J49/38

Abstract: The present invention relates to methods for the diagnosis and risk assessment of plasmalogen deficiency mediated diseases of aging. The present invention describes the relationship between plasmalogen biosynthesis dysfunction and the biochemical and clinical manifestations of age related disorders. Specifically the present invention describes an increased prevalence of colon cancer, prostate cancer, lung cancer, breast cancer, ovary cancer, kidney cancer, cognitive impairment and dementia in subjects suffering from adult onset plasmalogen biosynthesis disorder (AO-PBD).

Abstract translation: 本发明涉及用于诊断和评估缺血性贫血的老化疾病的方法。 本发明描述了质膜生物合成功能障碍与年龄相关疾病的生化和临床表现之间的关系。 具体地说，本发明描述了患有成人起始型血浆原生质合成障碍（AO-PBD）的受试者中结肠癌，前列腺癌，肺癌，乳腺癌，卵巢癌，肾癌，认知障碍和痴呆症的患病率增加。

公开(公告)号：US20060080042A1

公开(公告)日：2006-04-13

申请号：US11273570

申请日：2005-11-14

Applicant: Dayan Goodenowe

Inventor： Dayan Goodenowe

IPC: G06F19/00

CPC classification number: G01N33/6848 ,  G16B20/00 ,  G16B50/00 ,  G16C20/20 ,  G16C20/90 ,  H01J49/38 ,  Y10S707/99936 ,  Y10S707/99943

Abstract: A method for non-targeted complex sample analysis which involves the following steps. A first step involves providing a database (16) containing identifying data of known molecules. A second step involves introducing a complex sample containing multiple unidentified molecules into a Fourier Transform Ion Cyclotron Mass Spectrometer (12) to obtain data regarding the molecules in the complex sample. A third step involves comparing the collected data regarding the molecules in the complex sample with the identifying data of known molecules in order to arrive at an identification through comparison of the molecules in the sample.

Abstract translation: 一种非目标复杂样本分析方法，涉及以下步骤。 第一步涉及提供包含已知分子的识别数据的数据库（16）。 第二步涉及将含有多个不明分子的复杂样品引入傅里叶变换离子回旋加速器质谱仪（12），以获得有关复合物样品中分子的数据。 第三步涉及将收集到的关于复合物样品中的分子的数据与已知分子的鉴定数据进行比较，以通过比较样品中的分子来获得鉴定。

公开(公告)号：US20160320366A1

公开(公告)日：2016-11-03

申请号：US15143064

申请日：2016-04-29

Applicant: Dayan Goodenowe

Inventor： Dayan Goodenowe

IPC: G01N33/49 ,  H01J49/38 ,  H01J49/00

CPC classification number: G01N33/49 ,  G01N33/57484 ,  G01N33/6896 ,  G01N33/92 ,  G01N2560/00 ,  G01N2800/50 ,  G01N2800/7042 ,  H01J49/0031 ,  H01J49/38

Abstract: The present invention relates to methods for the diagnosis and risk assessment of plasmalogen deficiency mediated diseases of aging. The present invention describes the relationship between plasmalogen biosynthesis dysfunction and the biochemical and clinical manifestations of age related disorders. Specifically the present invention describes an increased prevalence of colon cancer, prostate cancer, lung cancer, breast cancer, ovary cancer, kidney cancer, cognitive impairment and dementia in subjects suffering from adult onset plasmalogen biosynthesis disorder (AO-PBD).

Abstract translation: 本发明涉及用于诊断和评估缺血性贫血的老化疾病的方法。 本发明描述了质膜生物合成功能障碍与年龄相关疾病的生化和临床表现之间的关系。 具体地说，本发明描述了患有成人起始型血浆原生质合成障碍（AO-PBD）的受试者中结肠癌，前列腺癌，肺癌，乳腺癌，卵巢癌，肾癌，认知障碍和痴呆症的患病率增加。